nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

01.02.2014

Targeting Inflammation: Impact on Atherothrombosis

verfasst von: Maria Giulia Marini, Chiara Sonnino, Marco Previtero, Luigi M. Biasucci

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Atherothrombosis is a worldwide epidemic accounting for an unacceptable toll of deaths and disabilities. Its pathophysiology is complex and hardly referable to a specific mechanism; however, in the last 20 years, a growing amount of evidence has demonstrated that inflammatory processes play a major role from the very beginning to the ultimate complication of atherothrombosis. These evidences are addressing a growing interest toward anti-inflammatory agents as preventive or curative treatments of atherothrombosis. At present, accumulated data are not conclusive, but strong evidence exists in favor of an anti-inflammatory positive effect for several drugs as statins or renin–angiotensin inhibitors. More conclusive data are expected from ongoing trials directly exploring the role of specific cytokines antagonists.

Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380, 2095–2128. doi:10.1016/S0140-6736(12)61728-0.PubMed

Libby, P. (2012). Inflammation in atherosclerosis. Atherosclerosis Thrombosis Vascular Biology, 32(9), 2045–2051. doi:10.1161/ATVBAHA.108.179705.

Jonasson, L., Holm, J., Skalli, O., Bondjers, G., & Hansson, G. K. (1986). Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis, 6(2), 131–138.PubMed

Woollard, K. J., & Geissmann, F. (2010). Monocytes in atherosclerosis: subsets and functions. Nature Reviews Cardiology, 7(2), 77–86. doi:10.1038/nrcardio.2009.228.PubMedCentralPubMed

Wyss, C. A., Neidhart, M., Altwegg, L., Spanaus, K. S., Yonekawa, K., Wischnewsky, M. B., et al. (2010). Cellular actors, toll-like receptors, and local cytokine profile in acute coronary syndromes. European Heart Journal, 31, 1457–1469. doi:10.1093/eurheartj/ehq084.PubMed

Yonekawa, K., Neidhart, M., Altwegg, L. A., Wyss, C. A., Corti, R., Vogl, T., et al. (2011). Myeloid related proteins activate toll-like receptor 4 in human acute coronary syndromes. Atherosclerosis, 218(2), 486–492. doi:10.1016/j.atherosclerosis.2011.06.020.PubMed

Niessner, A., Shin, M. S., Pryshchep, O., Goronzy, J. J., Chaikof, E. L., & Weyand, C. M. (2007). Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation, 116(18), 2043–2052.PubMed

Libby, P., & Ridker, P. M. (2009). Hansson GK; Leducq Transatlantic Network on Atherothrombosis: Inflammation in atherosclerosis: from pathophysiology to practice J. American College of Cardiology, 54(23), 2129–2138. doi:10.1016/j.jacc.2009.09.009.

Hansson, G. K. (2005). Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine, 352(16), 1685–1695.PubMed

10.

Narducci, M. L., Grasselli, A., Biasucci, L. M., Farsetti, A., Mulè, A., Liuzzo, G., et al. (2007). High telomerase activity in neutrophils from unstable coronary plaques. Journal of the American College of Cardiology, 50(25), 2369–2374.PubMed

11.

Biasucci, L. M., Liuzzo, G., Giubilato, S., Della Bona, R., Leo, M., Pinnelli, M., et al. (2009). Delayed neutrophil apoptosis in patients with unstable angina: relation to C-reactive protein and recurrence of instability. European Heart Journal, 30(18), 2220–2225. doi:10.1093/eurheartj/ehp248.PubMed

12.

Freedman, J. E., Larson, M. G., Tanriverdi, K., O'Donnell, C. J., Morin, K., Hakanson, A. S., et al. (2010). Relation of platelet and leukocyte inflammatory transcripts to body mass index in the Framingham heart study. Circulation, 122(2), 119–129. doi:10.1161/CIRCULATIONAHA.109.928192.PubMedCentralPubMed

13.

Zal, B., Kaski, J. C., Arno, G., Akiyu, J. P., Xu, Q., Cole, D., et al. (2004). Heat-shock protein 60-reactive CD4 + CD28null T cells in patients with acute coronary syndromes. Circulation, 109(10), 1230–1235.PubMed

14.

Nakajima, H., Kobayashi, J., Bando, K., Niwaya, K., Tagusari, O., Sasako, Y., et al. (2002). The effect of cryo-maze procedure on early and intermediate term outcome in mitral valve disease: case matched study. Circulation, 106(12 Suppl 1), I46–I50.PubMed

15.

Libby, P. (2009). Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. Journal of Lipid Research, 50(Suppl), S352–S357. doi:10.1194/jlr.R800099-JLR200.PubMed

16.

Liuzzo, G., Biasucci, L. M., Trotta, G., Brugaletta, S., Pinnelli, M., Digianuario, G., et al. (2007). Unusual CD4 + CD28null T lymphocytes and recurrence of acute coronary events. Journal of the American College of Cardiology, 50(15), 1450–1458.PubMed

17.

Miossec, P., Korn, T., & Kuchroo, V. K. (2009). Interleukin-17 and type 17 helper T cells. The New England Journal of Medicine, 361(9), 888–898. doi:10.1056/NEJMra0707449.PubMed

18.

Chen, S., Crother, T. R., & Arditi, M. (2010). Emerging role of IL-17 in atherosclerosis. Journal of Innate Immunity, 2(4), 325–333. doi:10.1159/000314626.PubMed

19.

Brusko, T. M., Putnam, A. L., & Bluestone, J. A. (2008). Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunological Reviews, 223, 371–390. doi:10.1111/j.1600-065X.2008.00637.x.PubMed

20.

Mor, A., Luboshits, G., Planer, D., Keren, G., & George, J. (2006). Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. European Heart Journal, 27(21), 2530–2537.PubMed

21.

Han, S. F., Liu, P., Zhang, W., Bu, L., Shen, M., Li, H., et al. (2007). The opposite-direction modulation of CD4 + CD25+ Tregs and T helper 1 cells in acute coronary syndromes. Clinical Immunology, 124(1), 90–97.PubMed

22.

Liuzzo, G., Goronzy, J. J., Yang, H., Kopecky, S. L., Holmes, D. R., Frye, R. L., et al. (2000). Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation, 101(25), 2883–2888.PubMed

23.

De Palma, R., Del Galdo, F., Abbate, G., Chiariello, M., Calabró, R., Forte, L., et al. (2006). Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: evidence for a local, intracoronary immunologic mechanism. Circulation, 113(5), 640–646.PubMed

24.

Vigushin, D. M., Pepys, M. B., & Hawkins, P. N. (1993). Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. The Journal of Clinical Investigation, 91(4), 1351–1357.PubMedCentralPubMed

25.

Biasucci, L. M. (2004). CDC; AHA: Clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice. Circulation, 110(25), e560–e567.PubMed

26.

Biasucci, L.M, Koenig, W., Mair, J., Mueller, C., Plebani, M., Lindahl, B., Rifai, N., Venge, P., Hamm, C., Giannitsis, E., Huber, K., Galvani, M., Tubaro, M., Collinson, P., Alpert, J.S., Hasin, Y., Katus, H., Jaffe, A.S., Thygesen, K. (2013). the Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association of the European Society of Cardiology. European Heart Journal, in press

27.

Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., et al. (1994). The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. The New England Journal of Medicine, 331(7), 417–422.PubMed

28.

Biasucci, L. M., Liuzzo, G., Grillo, R. L., Caligiuri, G., Rebuzzi, A. G., Buffon, A., et al. (1999). Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation, 99(7), 855–860.PubMed

29.

Kuller, L. H., Tracy, R. P., Shaten, J., & Meilahn, E. N. (1996). Relation of C-reactive protein and coronary heart disease in the MRFIT nested case–control study. Multiple risk factor intervention trial. American Journal of Epidemiology, 144(6), 537–547.PubMed

30.

Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997). Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. The New England Journal of Medicine, 336(14), 973–979.PubMed

31.

Kaptoge, S., Di Angelantonio, E., Lowe, G., Pepys, M. B., Thompson, S. G., Collins, R., et al. (2010). C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet, 375(9709), 132–140. doi:10.1016/S0140-6736(09)61717-7.PubMed

32.

Patrono, C., García Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005). Low-dose aspirin for the prevention of atherothrombosis. The New England Journal of Medicine, 353(22), 2373–2383.PubMed

33.

Larsen, S. B., Grove, E. L., Kristensen, S. D., & Hvas, A. M. (2013). Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. Thrombosis and Haemostasis, 109(5), 920–929. doi:10.1160/TH12-09-0666.PubMed

34.

Yuan, Z., Shioji, K., Kihara, Y., Takenaka, H., Onozawa, Y., & Kishimoto, C. (2004). Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. American Journal of Physiology - Heart and Circulatory Physiology, 286(1), H83–H90.PubMed

35.

Wolf, S. C., Sauter, G., Preyer, M., Poerner, T., Kempf, V. A., Risler, T., et al. (2007). Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiology Biochemistry, 19(1–4), 129–136.

36.

Biasucci, L. M., Lombardi, M., Piro, M., Di Giannuario, G., Liuzzo, G., & Crea, F. (2005). Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina. Heart, 91(5), 670–671.PubMed

37.

Destro, M., Cagnoni, F., Dognini, G. P., Galimberti, V., Taietti, C., Cavalleri, C., et al. (2011). Telmisartan: just an antihypertensive agent? A literature review. Expert Opinion on Pharmacotherapy, 12(17), 2719–2735. doi:10.1517/14656566.2011.632367.PubMed

38.

Porto, I., Di Vito, L., De Maria, G. L., Dato, I., Tritarelli, A., Leone, A. M., et al. (2009). Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome. The American Journal of Cardiology, 103(11), 1500–1505. doi:10.1016/j.amjcard.2009.01.370.PubMed

39.

Lopez Santi, R. G., Valeff, E. C., Duymovich, C. R., Mazziotta, D., Mijailovsky, N. E., Filippa, G. C., et al. (2005). Etchegoyen MC; PROCORDIS investigators: Effects of an angiotensin-converting enzyme inhibitor: (ramipril) on inflammatory markers in secondary prevention patients: RAICES Study. Coronary Artery Disease, 16(7), 423–429.PubMed

40.

Verma, S., Lonn, E. M., Nanji, A., Browne, K., Ward, R., Robertson, A., et al. (2009). Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive protein randomized evaluation: (4R) trial results. The Canadian Journal of Cardiology, 25(7), e236–e240.PubMed

41.

Vicenová, B., Vopálenskẏ, V., Burẏsek, L., & Pospísek, M. (2009). Emerging role of interleukin-1 in cardiovascular diseases. Physiological Research, 58, 481–498.PubMed

42.

Merhi-Soussi, F., Kwak, B. R., Magne, D., et al. (2005). Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovascular Research, 66(3), 583–593.PubMed

43.

Isoda, K., Sawada, S., Ishigami, N., et al. (2004). Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(6), 1068–1073.PubMed

44.

Bujak, M., & Frangogiannis, N. G. (2009). The role of IL-1 in the pathogenesis of heart disease. Archivum Immunologiae et Therapiae Experimentalis (Warsz), 57(3), 165–176. doi:10.1007/s00005-009-0024-y.

45.

Kaplanski, G., Porat, R., Aiura, K., Erban, J. K., Gelfand, J. A., & Dinarello, C. A. (1993). Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. Blood, 81(10), 2492–2495.PubMed

46.

Fearon, W. F., & Fearon, D. T. (2008). Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation, 117(20), 2577–2579. doi:10.1161/CIRCULATIONAHA.108.772491.PubMed

47.

Abbate, A., Salloum, F. N., Vecile, E., Das, A., Hoke, N. N., Straino, S., et al. (2008). Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation, 117(20), 2670–2683. doi:10.1161/CIRCULATIONAHA.107.740233.PubMed

48.

Abbate, A., Kontos, M. C., Grizzard, J. D., Biondi-Zoccai, G. G., Van Tassell, B. W., Robati, R., et al. (2010). VCU-ART Investigators: Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). American Journal of Cardiology, 105(10), 1371–1377.e1. doi:10.1016/j.amjcard.2009.12.059.PubMed

49.

Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011). Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab anti-inflammatory Thrombosis Outcomes Study (CANTOS). American Heart Journal, 162(4), 597–605. doi:10.1016/j.ahj.2011.06.012.PubMed

50.

Pasceri, V., & Yeh, E. T. (1999). A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation, 100(21), 2124–2126.PubMed

51.

Walsh, L. J., Trinchieri, G., Waldorf, H. A., Whitaker, D., & Murphy, G. F. (1991). Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proceedings of the National Academy of Sciences of the United States of America, 88(10), 4220–4224.PubMedCentralPubMed

52.

Liuzzo, G., Kopecky, S. L., Frye, R. L., O'Fallon, W. M., Maseri, A., Goronzy, J. J., et al. (1999). Perturbation of the T-cell repertoire in patients with unstable angina. Circulation, 100(21), 2135–2139.PubMed

53.

Schmidt, D., Goronzy, J. J., & Weyand, C. M. (1996). CD4+ CD7–CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. The Journal of Clinical Investigation, 97(9), 2027–2037.PubMedCentralPubMed

54.

Rizzello, V., Liuzzo, G., Brugaletta, S., Rebuzzi, A., Biasucci, L. M., & Crea, F. (2006). Modulation of CD4(+)CD28null T lymphocytes by tumor necrosis factor-alpha blockade in patients with unstable angina. Circulation, 113(19), 2272–2277.PubMed

55.

Chung, E. S., Packer, M., Lo, K. H., & Fasanmade, A. A. (2003). Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation, 107(25), 3133–3140.PubMed

56.

Ridker, P. M. (2009). Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). Journal of Thrombosis and Haemostasis, 7(Suppl 1), 332–339. doi:10.1111/j.1538-7836.2009.03404.x.PubMed

57.

Elango, T., Dayalan, H., Subramanian, S., Gnanaraj, P., & Malligarjunan, H. (2012). Serum interleukin-6 levels in response to methotrexate treatment in psoriatic patients. Clinica Chimica Acta, 413(19–20), 1652–1656. doi:10.1016/j.cca.2012.05.007.

58.

Gerards, A. H., de Lathouder, S., de Groot, E. R., Dijkmans, B. A., & Aarden, L. A. (2003). Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford), 42(10), 1189–1196.

59.

Ridker, P. M. (2013). Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? Current Atherosclerosis Reports, 15(1), 295. doi:10.1007/s11883-012-0295-3.PubMed

60.

Coomes, E., Chan, E. S., & Reiss, A. B. (2011). Methotrexate in atherogenesis and cholesterol metabolism. Cholesterol. doi:10.1155/2011/503028. 503028.PubMedCentralPubMed

61.

Reiss, A. B., Carsons, S. E., Anwar, K., Rao, S., Edelman, S. D., Zhang, H., et al. (2008). Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis and Rheumatism, 58(12), 3675–3683. doi:10.1002/art.24040.PubMedCentralPubMed

62.

Bulgarelli, A., Martins Dias, A. A., Caramelli, B., & Maranhao, R. C. (2012). Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. Journal of Cardiovascular Pharmacology, 59(4), 308–314. doi:10.1097/FJC.0b013e318241c385.PubMed

63.

Micha, R., & Imamura, F. (2011). Wyler von Ballmoos M, Solomon DH, Hernán MA, Ridker PM, Mozaffarian D: Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. The American Journal of Cardiology, 108(9), 1362–1370. doi:10.1016/j.amjcard.2011.06.054.PubMedCentralPubMed

64.

Abbate, A., Santini, D., Biondi-Zoccai, G. G., Scarpa, S., Vasaturo, F., Liuzzo, G., et al. (2004). Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe? Heart, 90(4), 440–443.PubMed

65.

Baker, C. S., Hall, R. J., Evans, T. J., et al. (1999). Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 19(3), 646–655.PubMed

66.

Schönbeck, U., Sukhova, G. K., Graber, P., Coulter, S., & Libby, P. (1999). Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. The American Journal of Pathology, 155(4), 1281–1291.PubMed

67.

Willoughby, D. A., Moore, A. R., & Colville-Nash, P. R. (2000). COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet, 355(9204), 646–648.PubMed

68.

Saito, T., Rodger, I. W., Hu, F., Shennib, H., & Giaid, A. (2000). Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochemical and Biophysical Research Communications, 273(2), 772–775.PubMed

69.

Abbate, A., Limana, F., Capogrossi, M. C., Santini, D., Biondi-Zoccai, G. G., Scarpa, S., et al. (2006). Cyclo-oxygenase-2 (COX-2) inhibition reduces apoptosis in acute myocardial infarction. Apoptosis, 11(6), 1061–1063.PubMed

70.

Bombardier, C., Laine, L., Reicin, A., et al. (2000). VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New England Journal of Medicine, 343(21), 1520–1528. 2 pp following 1528.PubMed

71.

Bresalier, R. S., Sandler, R. S., Quan, H., et al. (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The New England Journal of Medicine, 352(11), 1092–1102.PubMed

72.

Farmer, J. A. (2000). Pleiotropic effects of statins. Current Atherosclerosis Reports, 2(3), 208–217.PubMed

73.

Heart Protection Study Collaborative Group. (2002). MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360(9326), 7–22.

74.

Amarenco, P., Bogousslavsky, J., Callahan, A., 3rd, Goldstein, L. B., Hennerici, M., Rudolph, A. E., et al. (2006). Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. The New England Journal of Medicine, 355(6), 549–559.PubMed

75.

Shahar, E., Chambless, L. E., Rosamond, W. D., Boland, L. L., Ballantyne, C. M., & McGovern, P. G. (2003). Sharrett AR; Atherosclerosis Risk in Communities Study: Plasma lipid profile and incident ischemic stroke. Stroke, 34(3), 623–631.PubMed

76.

Brugaletta, S., Biasucci, L. M., Pinnelli, M., Biondi-Zoccai, G., Di Giannuario, G., Trotta, G., et al. (2006). Novel anti-inflammatory effect of statins: reduction of CD4 + CD28null T lymphocyte frequency in patients with unstable angina. Heart, 92(2), 249–250.PubMed

77.

Lijnen, P., Echevaria-Vazquez, D., & Petrov, V. (1996). Influence of cholesterol lowering on plasma membrane lipids and function. Methods and Findings in Experimental and Clinical Pharmacology, 18(2), 123–136.PubMed

78.

Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., et al. (1998). Braunwald E; Cholesterol and Recurrent Events (CARE) Investigators: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation, 98(9), 839–844.PubMed

79.

Patel, M.J., Blazing, M.A. (2013) Inflammation and atherosclerosis: disease modulating therapies. Current Treat Options Cardiovascular Medicine. 15(6):681–695.

80.

Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., et al. (2001). Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. The New England Journal of Medicine, 344(26), 1959–1965.PubMed

81.

Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., et al. (2005). Braunwald E; Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators: Pravastatin or atorvastatin evaluation and infection therapy: C-reactive protein levels and outcomes after statin therapy. The New England Journal of Medicine, 352(1), 20–28.PubMed

82.

Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., et al. (2005). Ganz P; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. The New England Journal of Medicine, 352(1), 29–38.PubMed

83.

Albert, M. A., Danielson, E., & Rifai, N. (2001). Ridker PM; PRINCE Investigators: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA, 286(1), 64–70.PubMed

84.

Ridker, P. M., & JUPITER Study Group. (2003). Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation, 108(19), 2292–2297.PubMed

85.

Yousuf, O., Mohanty, B. D., Martin, S. S., Joshi, P. H., Blaha, M. J., Nasir, K., et al. (2013). High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link. Journal of the American College of Cardiology, 62(5), 397–408. doi:10.1016/j.jacc.2013.05.016.PubMed

86.

Kaul, S., Morrissey, R. P., & Diamond, G. A. (2010). By Jove! What is a clinician to make of JUPITER? Arch. Internal Medicine, 170(12), 1073–1077. doi:10.1001/archinternmed.2010.189.

87.

Ridker, P. M., & Glynn, R. J. (2010). The JUPITER trial: responding to the critics. The American Journal of Cardiology, 106(9), 1351–1356. doi:10.1016/j.amjcard.2010.08.025.PubMed

88.

Chu, A. Y., Guilianini, F., Barratt, B. J., Nyberg, F., Chasman, D. I., & Ridker, P. M. (2012). Pharmacogenetic determinants of statin-induced reduction in C-reactive protein. Circulation Cardiovascular Genetics, 5(1), 58–65. doi:10.1161/CIRCGENETICS.111.961847.PubMed

89.

Chasman, D. I., Guilianini, F., MacFadyen, J., Barratt, B. J., Nyberg, F., Ridker, P. M., et al. (2012). Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction. The justificaton for the use of statins in prevention: an intervention trial evalauting rosuvastatin (JUPITER) trial. Circulation Cardiovascular Genetics, 5, 257–264. doi:10.1161/CIRCGENETICS.111.961144.PubMed

90.

Burke, J. E., & Dennis, E. A. (2009). Phospholipase A2 biochemistry. Cardiovascular Drugs and Therapy, 23(1), 49–59. doi:10.1007/s10557-008-6132-9.PubMedCentralPubMed

91.

Rosenson, R. S. (2009). Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovascular Drugs and Therapy, 23(1), 93–101. doi:10.1007/s10557-008-6148-1.PubMed

92.

White, H., Held, C., Stewart, R., Watson, D., Harrington, R., Budaj, A., et al. (2010). Study design and rationale for the clinical outcomes of the STABILITY trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib vs. placebo in patients with coronary heart disease. American Heart Journal, 160(4), 655–661. doi:10.1016/j.ahj.2010.07.006.PubMed

93.

O’Donoghue, M. L., Braunwald, E., White, H. D., Serruys, P., Steg, P. G., Hochman, J., et al. (2011). Study design and rationale for the Stabilization Of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. American Heart Journal, 162(4), 613–619.e1. doi:10.1016/j.ahj.2011.07.018.PubMed

94.

García-García, H. M., Klauss, V., Gonzalo, N., Garg, S., Onuma, Y., Hamm, C. W., et al. (2012). Relationship between cardiovascular risk factors and biomarkers with necrotic core and atheroma size: a serial intravascular ultrasound radiofrequency data analysis. The International Journal of Cardiovascular Imaging, 28(4), 695–703. doi:10.1007/s10554-011-9882-6.PubMedCentralPubMed

95.

Nicholls, S. J., Cavender, M. A., Kastelein, J. J., Schwartz, G., Waters, D. D., Rosenson, R. S., et al. (2012). Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovascular Drugs and Therapy, 26(1), 71–75. doi:10.1007/s10557-011-6358-9.PubMed

96.

Epstein, S. E., Zhu, J., Najafi, A. H., & Burnett, M. S. (2009). Insights into the role of infection in atherogenesis and in plaque rupture. Circulation, 119(24), 3133–3141. doi:10.1161/CIRCULATIONAHA.109.849455.PubMed

97.

Biasucci, L. M., Liuzzo, G., Ciervo, A., et al. (2003). Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes. Circulation, 107(24), 3015–3017.PubMed

98.

Liuzzo, G., Ciervo, A., Niccoli, G., et al. (2011). Chlamydia pneumoniae in coronary atherosclerotic plaques and coronary instability. International Journal of Cardiology, 147(1), 176–178. doi:10.1016/j.ijcard.2010.12.029.PubMed

99.

Rosenfeld, M. E., & Campbell, L. A. (2011). Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thrombosis and Haemostasis, 106(5), 858–867. doi:10.1160/TH11-06-0392.PubMed

100.

Grayston, J. T. (2003). Antibiotic treatment of atherosclerotic cardiovascular disease. Circulation, 107(9), 1228–1230.PubMed

101.

O'Connor, C. M., et al. (2003). Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. Journal of the American Medical Association, 290(11), 1459–1466.PubMed

102.

Grayston, J. T., et al. (2005). Azithromycin for the secondary prevention of coronary events. The New England Journal of Medicine, 352(16), 1637–1645.PubMed

103.

Cannon, C. P., et al. (2005). Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. The New England Journal of Medicine, 352(16), 1646–1654.PubMed

104.

Jespersen, C. M., et al. (2006). Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. British Medical Journal, 332(7532), 22–27.PubMed

105.

Danesh, J. (2005). Antibiotics in the prevention of heart attacks. Lancet, 365(9457), 365–367.PubMed

106.

Caroli, A., Cardillo, M. T., Galea, R., & Biasucci, L. M. (2013). Potential therapeutic role of microRNAs in ischemic heart disease. Journal of Cardiology, 61(5), 315–320. doi:10.1016/j.jjcc.2013.01.012.PubMed

Titel: Targeting Inflammation: Impact on Atherothrombosis
verfasst von: Maria Giulia Marini
Chiara Sonnino
Marco Previtero
Luigi M. Biasucci
Publikationsdatum: 01.02.2014
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 1/2014
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-013-9523-7

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Bridging antiplatelet therapy in patients requiring cardiac and non-cardiac surgery: from bench to bedside

Impact of Mild Hypothermia on Platelet Responsiveness to Aspirin and Clopidogrel: an In Vitro Pharmacodynamic Investigation

Lessons Learned from Negative Clinical Trials Evaluating Antithrombotic Therapy for Ischemic Heart Disease

Scientific Foundation and Possible Implications for Practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX (MATRIX) Trial